1. Home
  2. VALN vs GOSS Comparison

VALN vs GOSS Comparison

Compare VALN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$9.72

Market Cap

820.0M

Sector

Health Care

ML Signal

HOLD

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$2.54

Market Cap

796.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALN
GOSS
Founded
2012
2015
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
820.0M
796.2M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
VALN
GOSS
Price
$9.72
$2.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$15.75
$8.60
AVG Volume (30 Days)
25.2K
4.5M
Earning Date
11-20-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$211,089,992.00
$44,051,000.00
Revenue This Year
$3.64
N/A
Revenue Next Year
$12.23
$6.41
P/E Ratio
N/A
N/A
Revenue Growth
13.48
N/A
52 Week Low
$4.20
$0.76
52 Week High
$12.25
$3.87

Technical Indicators

Market Signals
Indicator
VALN
GOSS
Relative Strength Index (RSI) 65.65 32.83
Support Level $8.77 $3.04
Resistance Level $8.98 $3.87
Average True Range (ATR) 0.35 0.28
MACD 0.14 -0.13
Stochastic Oscillator 91.54 0.74

Price Performance

Historical Comparison
VALN
GOSS

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: